|
|
|
|
|
|
By Nathalie Huther, Ph.D., MBA and Carlos N Velez, Ph.D., MBA | With increasingly complex modalities, undruggable targets, rare diseases, and narrowly defined patient subpopulations, CMC is an important area of due diligence scrutiny for prospective investors and licensees. Part 1 of a two-part analysis. | |
|
|
| 8 Key Partner Quality Attributes Your CDMO Must Have | Article | By Pauline Ginsberg, PMP, INCOG BioPharma Services | CDMOs help reduce the complexity and costs of drug development and manufacturing, making the right CDMO partner essential for many biopharma companies. |
|
|
| A New Paradigm In T-Cell Lymphoma Treatment: CD5 CAR-NK | Article | By Seungryel Han and Miyoung Jung, GC Cell | T-cell lymphomas are a complex and increasingly prevalent group of cancers with poor survival outcomes and limited effective treatments, underscoring an urgent need for innovative therapies and novel targets. |
|
|
|
|
|
|
|
|
|
| Multispecific molecules bring added complexity to downstream purification—think incorrect chain pairings, aggregation, fragmentation, and lower yields. Join Bioprocess Online Live as we explore how developers are addressing these challenges to achieve high purity and efficient processes. Gain insights into key considerations for downstream teams when designing purification strategies for these advanced biologics. Registration is free thanks to the support of Thermo Fisher Scientific. |
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
